ArticleBMC gastroenterology2025
Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DEB-TACE Combined with Immunotherapy and Targeted Therapy for Advanced Hepatocellular Carcinoma with Scapular Metastasis: A Case Report.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransarterial chemoembolization (TACE) is a standard treatment for unresectable hepatocellular carcinoma (HCC). However, a significant proportion of patients develop conventional TACE (cTACE) refractoriness, which is associated with poor prognosis. The optimal treatment strategy for cTACE-refractory HCC remains controversial. This study aimed to evaluate the efficacy and safety of drug-eluting bead TACE (D-TACE) combined with lenvatinib versus cTACE plus lenvatinib in patients with cTACE-refractory HCC.
methodsWe conducted a retrospective analysis of 103 patients with cTACE-refractory unresectable HCC treated at our institution between January 2019 and June 2021. Patients were divided into two groups: the D-TACE + lenvatinib group (n = 48) and the cTACE + lenvatinib group (n = 55). The primary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) assessed according to mRECIST criteria. Secondary endpoints included safety profiles and changes in liver function parameters.
resultsThe D-TACE + lenvatinib group demonstrated significantly better treatment outcomes compared to the cTACE + lenvatinib group. The ORR was 50.0% versus 21.8% (P = 0.004), and the DCR was 83.3% versus 61.8% (P = 0.017), respectively. The median PFS was significantly longer in the D-TACE combination group (8.7 months vs. 6.6 months, P = 0.002). Similarly, the median OS was significantly improved with D-TACE plus lenvatinib (20.3 months vs. 15.2 months, P = 0.001). The incidence of vomiting (all grades) was lower in the D-TACE group (31.2% vs. 50.9%, P = 0.048), while other adverse events were comparable between groups. No significant differences were observed in liver function parameters or hematological indices at 3-month follow-up.
conclusionsFor patients with cTACE-refractory unresectable HCC, D-TACE combined with lenvatinib demonstrates superior efficacy compared to cTACE plus lenvatinib, with significantly improved ORR, DCR, PFS, and OS, and a comparable safety profile. This combination represents an effective and safe treatment strategy for this challenging patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.